Similarly, a stage III clinical trial found that positivity for at least two out of three CTC biomarkers (MART-1, GalNAc-T and MAGE-A3) examined was significantly associated with decreased recurrence-free survival in patients with stage II melanoma and metastases to sentinel lymph nodes [330]. This evidence concerns the gene MAGEA3 and melanoma.